|Event Time:||Wednesday April 30, 2014 2:00 pm to 6:00 pm|
|Topic(s):||General Neurology, Research Methodology, Education, and History|
|Director(s):||Barbara Vickrey MD, MPH, FAAN, Linda Williams MD, FAAN|
|Description:||Once a trial establishing the efficacy of a new treatment is published, many questions remain to be answered before a neurologist in practice can apply that new knowledge in a way to produce the full health benefit for individual patients and across that neurologist's entire practice. "Outcomes research" encompasses a broad range of topics that are intended to fill the gap between clinical trial findings and improved health of patients under physicians' care. In this session, research in 4 key areas that are critical to consider - once the "dust settles" on a randomized clinical trial publication - are illustrated, and the current status of each of these areas in neurology is summarized. These 4 key areas are (1) effectiveness, or to what extent the benefits and risks of the new treatment are similar in a “real world” practice setting rather than a clinical trial; (2) decision support, or approaches utilizing technology and building on the science of decision-making and cognitive psychology, to help neurologists apply complex clinical trial findings appropriately and fully; (3) incorporation of patient preferences in decisions about new treatments, particularly relevant for treatments for which there are risks and benefits that involve tradeoffs on which the patient must weigh in to make sure that treatment decisions yield the best outcomes; and (4) implementation of a new intervention, including coordinated care delivery models, where the context of care and the methods of implementing an intervention in a given practice setting may impact patient outcomes. Opportunities for neurologists in academic and private practice to shape this research agenda and participate in "field" work will be highlighted.|
|2:00 PM - 2:10 PM||Introduction||Faculty|
|2:10 PM - 2:40 PM||Intervention Research on Improving Access to and Quality of Neurologic Care||E. Ray Dorsey MD, MBA|
|2:40 PM - 3:10 PM||Effectiveness Research in Neurology||Seemant Chaturvedi MD, FAAN, FAHA|
|3:10 PM - 3:40 PM||Translating Neurologic Advancements into Practice through Decision Support||Eric M. Cheng MD, MS, FAAN|
|3:40 PM - 4:10 PM||Research on Incorporating Patient Preferences in Neurologic Care||Adam Kelly MD, FAAN|
|4:10 PM - 4:30 PM||Questions and Answers||Faculty|
|4:30 PM - 5:30 PM||Poster Rounds||None|
|5:30 PM - 6:00 PM||Data Blitz||None|
|Seemant Chaturvedi, MD, FAAN, FAHA||Dr. Chaturvedi has received personal compensation in an editorial capacity for NEJM Journal Watch Neurology. Dr. Chaturvedi has received research support from Boehringer Ingelheim.|
|Eric M. Cheng, MD, MS, FAAN||Dr. Cheng has nothing to disclose.|
|E. Ray Dorsey, MD, MBA||Dr. Dorsey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with 23andMe, Abbott, Abbvie, American Well, Biogen, Clintrex, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Karger, Lundbeck, MC10, MedAvante, Medical-legal services, Mednick Associates, National Institute of Neurological Disorders and Stroke, Olson Research Group, Optio, Prilenia, Putnam Associates, Roche, Sanofi, Shire, Sunovion Pharma, Teva, UCB, Voyager Therapeutics. Dr. Dorsey has received personal compensation in an editorial capacity for Karger Publications. Dr. Dorsey has received research support from Abbvie, Acadia Pharmaceuticals, AMC Health, Biosensics, Burroughs Wellcome Fund, GlaxoSmithKline, Nuredis Pharmaceuticals, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, Roche, and Teva Pharmaceuticals.|
|Adam Kelly, MD, FAAN||Dr. Kelly has nothing to disclose.|
|4:30 PM||001||Parkinson's Disease Patients' Preferences for Communication About Advanced Care Planning||
Keiran Tuck, MD
Dr. Tuck has nothing to disclose.
|4:30 PM||002||Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic: Prevalence and Development of a New Screening Strategy||
Herbert Manosalva Alzate, MD
Dr. Manosalva Alzate has nothing to disclose.
|4:30 PM||003||Multiple Sclerosis Documentation System MSDS3D - Innovative Management of Patients with Multiple Sclerosis||
Judith Eisele, M.D.
Dr. Eisele has nothing to disclose.
|4:30 PM||004||Neuro-oncology Telemedicine Follow-up Visits||
Richard Green, MD
Dr. Green has nothing to disclose.
|4:30 PM||005||Long Term Efficacy of Outpatient Interdisciplinary Treatment for Patients Suffering from Chronic Headaches||
Mark Stillman, MD, FAAN
Dr. Stillman has nothing to disclose.
|4:30 PM||006||Adherence to Oral Migraine Preventive Medications Among Patients with Chronic Migraine: Analysis of a Large US Health Insurance Claims Database||
Zsolt Hepp, PharmD, MS
Dr. Hepp has received personal compensation for activities with Allergan, Inc. as an employee.
|4:30 PM||007||Influence of CREST on CEA and CAS trends in women - do the results matter?||
Shahram Khalid, MD
Dr. Khalid has nothing to disclose.
|4:30 PM||008||Treatment Trends In Management Of Intracranial Stenosis In The Pre- And Post-Sammpris Era||
Swaroop Pawar, MD, MPH.
Dr. Pawar has nothing to disclose.
|4:30 PM||009||Antiepileptic Drug Prescribing for OEF/OIFVeterans with New-Onset Epilepsy: 2008-2010||
Mary Jo Pugh, PhD,RN
Dr. Pugh has received research support from Brain Sentinel.
|5:30 PM||001||Identifying Palliative Care Needs In The Neurological Intensive Care Unit||
Claire Creutzfeldt, MD
Dr. Creutzfeldt has nothing to disclose.
|5:35 PM||002||Appropriateness of Dopamine Antagonist Prescribing in Hospitalized Patients with Dopamine Requiring Diseases after Implementation of an Automated Prescribing Alert System||
Dr. Morris has nothing to disclose.
|5:40 PM||003||Development and Implementation of a Quality Improvement Strategy for Obtaining Muscle Biopsies Utilizing DMAIC Methodology||
Charles Kassardjian, MD
Dr. Kassardjian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme, Alexion, Takeda, Akcea.
|5:45 PM||004||A Comparison of Co-located and Traditional Outpatient Consultation for the Treatment of ADHD in Two Urban Medical Homes : Costs and Outcomes||
David Urion, MD
Dr. Urion has nothing to disclose.
|5:50 PM||005||Malformation risks of antiepileptic drug monotherapies in pregnancy: An update from the UK and Ireland Epilepsy and Pregnancy Registers||
Dr. Campbell has nothing to disclose.